© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
March 14, 2022
A recently published review delves into the role that type 2 inflammation plays chronic rhinosinusitis and the evidence that agents that interfere with that inflammatory pathway could be used as treatments.
November 05, 2021
Safety concerns may limit JAK inhibitors as treatment for the common skin condition.
October 08, 2021
Rinvoq, a JAK inhibitor, is still under review at the FDA as a treatment of atopic dermatitis.
October 07, 2021
Incyte will be required to conduct postmarketing study and set up patient registry to monitor whether the topical JAK inhibitor has adverse effects on mothers, fetuses and infants.